Boston Scientific Co. (NYSE:BSX) Shares Purchased by Cavalier Investments LLC

Cavalier Investments LLC raised its stake in Boston Scientific Co. (NYSE:BSX) by 148.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,431 shares of the medical equipment provider’s stock after acquiring an additional 106,590 shares during the period. Boston Scientific makes up about 5.3% of Cavalier Investments LLC’s portfolio, making the stock its 4th biggest holding. Cavalier Investments LLC’s holdings in Boston Scientific were worth $15,937,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Private Advisor Group LLC raised its holdings in Boston Scientific by 2.7% in the 3rd quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after acquiring an additional 944 shares in the last quarter. PFG Investments LLC raised its holdings in Boston Scientific by 3.3% in the 3rd quarter. PFG Investments LLC now owns 7,988 shares of the medical equipment provider’s stock valued at $669,000 after acquiring an additional 258 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Boston Scientific by 123.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 158,538 shares of the medical equipment provider’s stock worth $13,285,000 after buying an additional 87,470 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in shares of Boston Scientific by 11.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 13,718 shares of the medical equipment provider’s stock worth $1,150,000 after buying an additional 1,445 shares in the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Boston Scientific by 1.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 377,826 shares of the medical equipment provider’s stock worth $31,662,000 after buying an additional 4,959 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total transaction of $633,916.74. Following the sale, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 144,305 shares of company stock worth $14,954,985 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 3.3 %

NYSE BSX opened at $100.93 on Wednesday. The business’s 50-day moving average price is $98.46 and its two-hundred day moving average price is $89.87. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17. The firm has a market capitalization of $148.94 billion, a PE ratio of 80.74, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of research analyst reports. Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a report on Thursday, February 6th. Raymond James boosted their price target on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Royal Bank of Canada boosted their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, UBS Group boosted their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $107.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.